Saturday 17 October 2026
Export BDSX’s income statement to Excel — free account
Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
23.66
1.05
−4.25%
Follow BDSX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 4 | 4 |
+8 more TTM periods Free account |
| (540.01%) | (316.53%) | (383.09%) | (302.55%) | ||
| (30.33%) | (35.34%) | (38.18%) | (41.30%) | ||
ROIC |
(49.60%) | (51.87%) | (67.00%) | (70.66%) | |
Return on Tangible Assets |
(53.31%) | (63.14%) | (88.39%) | (97.11%) | |
Average Days of Receivables |
32.31 | 36.08 | 37.27 | 57.70 | |
Free Cash Flow per Share |
(1.98) | (2.61) | (3.14) | (3.91) | |
Free Cash Flow |
(20.40) | (25.25) | (23.67) | (29.33) | |
Capital Expenditures |
(0.57) | (0.41) | (0.40) | (1.18) | |
| Other line items | |||||
Cash ROIC |
(23.73%) | (31.10%) | (37.01%) | (47.30%) | |
Accounts Receivable Turnover |
12.43 | 11.21 | 10.03 | 7.74 | |
Accounts Payable Turnover |
7.02 | 5.24 | 6.34 | 5.26 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
43.78 | 77.38 | 67.24 | 81.58 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.93% | 12.92% | 13.56% | 14.40% | |
Selling, General and Administrative Expense of Revenue |
90.57% | 95.07% | 98.92% | 105.76% | |
Share Based Compensation of Revenue |
3.95% | 4.46% | 4.68% | 5.40% | |
Interest Coverage |
(2.55) | (3.11) | (3.61) | (4.39) | |
Operating CF/Net income |
0.71 | 0.78 | 0.66 | 0.71 | |
Depreciation/Fixed assets |
0.29 | 0.29 | 0.28 | 0.28 | |
Capex/Depreciation |
(0.08) | (0.06) | (0.06) | (0.17) | |
Revenue per Share |
10.00 | 9.95 | 11.72 | 10.69 | |
Operating CF per Share |
(1.93) | (2.57) | (3.08) | (3.75) | |
Capex per Share |
(0.06) | (0.04) | (0.05) | (0.16) | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.01 |
Columns are period end dates